Literature DB >> 20178687

Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro.

Yu Ren1, Chun-Sheng Kang, Xu-Bo Yuan, Xuan Zhou, Peng Xu, Lei Han, Guang Xiu Wang, Zhifan Jia, Yue Zhong, Shizhu Yu, Jing Sheng, Pei-Yu Pu.   

Abstract

MicroRNAs have been demonstrated to be deregulated in different types of cancer. miR-21 is a key player in the majority of cancers. Down-regulation of miR-21 in glioblastoma cells leads to repression of cell growth, increased cellular apoptosis and cell-cycle arrest, which can theoretically enhance the chemotherapeutic effect in cancer therapy. In this study, the poly(amidoamine) (PAMAM) dendrimer was employed as a carrier to co-deliver antisense-miR-21 oligonucleotide (as-miR-21) and 5-fluorouracil (5-FU) to achieve delivery of as-miR-21 to human glioblastoma cells and enhance the cytotoxicity of 5-FU antisense therapy. The inhibitory effect toward brain tumors was evaluated by MTT assay, and measurements of cell apoptosis and invasion using the human brain glioma cell line U251. PAMAM could be simultaneously loaded with 5-FU and as-miR-21, forming a complex smaller than 100 nm in diameter. Both the chemotherapeutant and as-miR-21 could be efficiently introduced into tumor cells. The co-delivery of as-miR-21 significantly improved the cytotoxicity of 5-FU and dramatically increased the apoptosis of U251 cells, while the migration ability of the tumor cells was decreased. These results suggest that our co-delivery system may have important clinical applications in the treatment of miR-21-overexpressing glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178687     DOI: 10.1163/156856209X415828

Source DB:  PubMed          Journal:  J Biomater Sci Polym Ed        ISSN: 0920-5063            Impact factor:   3.517


  63 in total

1.  MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).

Authors:  Nicola Valeri; Pierluigi Gasparini; Chiara Braconi; Alessio Paone; Francesca Lovat; Muller Fabbri; Khlea M Sumani; Hansjuerg Alder; Dino Amadori; Tushar Patel; Gerard J Nuovo; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients.

Authors:  Wang Xin Yuan; Yang Xi Gui; Wang Na Na; Jiang Chao; Xigui Yang
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

Review 3.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 4.  Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes.

Authors:  Rammohan Devulapally; Ramasamy Paulmurugan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-08-31

5.  Overcoming obstacles in microRNA delivery towards improved cancer therapy.

Authors:  Dikla Ben-Shushan; Ela Markovsky; Hadas Gibori; Galia Tiram; Anna Scomparin; Ronit Satchi-Fainaro
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 6.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

Review 7.  MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme.

Authors:  Pilar González-Gómez; Pilar Sánchez; Helena Mira
Journal:  Mol Neurobiol       Date:  2011-07-05       Impact factor: 5.590

8.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

9.  Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy.

Authors:  Nicole R Parker; Nelson Correia; Brendan Crossley; Michael E Buckland; Viive M Howell; Helen R Wheeler
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

Authors:  Yu Ren; Xuan Zhou; Mei Mei; Xu-Bo Yuan; Lei Han; Guang-Xiu Wang; Zhi-Fan Jia; Peng Xu; Pei-Yu Pu; Chun-Sheng Kang
Journal:  BMC Cancer       Date:  2010-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.